Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(NY:
GLS
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Apr 10, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about GLS
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer
April 03, 2023
From
Sight Sciences, Inc.
Via
GlobeNewswire
Gelesis Reports Fourth Quarter and Full Year 2022 Results
March 28, 2023
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Participate in the 25th Annual ICR Conference
January 05, 2023
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Reports Upcoming Participation in Wolfe Research’s Annual Consumer Growth Conference
November 21, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance
November 18, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Reports Third Quarter 2022 Results
November 14, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
November 07, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance
November 04, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics
November 02, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week
November 01, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit
September 08, 2022
From
Gelesis Holdings Inc.
Via
Business Wire
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
August 25, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET
August 17, 2022
From
Gelesis Holdings Inc.
Via
Business Wire
Gelesis Reports Second Quarter 2022 Results
August 15, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022
August 04, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
June 21, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study
June 05, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel
June 04, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Participate in Upcoming Investor Conferences
May 18, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis Reports First Quarter 2022 Results
May 12, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
May 09, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes
May 04, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
April 29, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
March 24, 2022
From
Gelesis Holdings, Inc.
Via
Business Wire
Gelesis to Report Full Year 2021 Financial Results on March 24, 2022
March 17, 2022
From
Gelesis, Inc.
Via
Business Wire
Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
March 16, 2022
From
Gelesis, Inc
Via
Business Wire
Plenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting Norms
January 31, 2022
From
Gelesis, Inc.
Via
Business Wire
Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar
January 13, 2022
From
Gelesis, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.